HTG Molecular Diagnostics Inc (STU:65H)
€ 0.242 0 (0%) Market Cap: 1,000.00 Enterprise Value: -2.44 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

HTG Molecular Diagnostics Inc Key Opinion Leader (KOL) “The Role of RNA Profiling in Drug Discovery and Analysis” - Corporate Call Transcript

Dec 13, 2022 / 04:00PM GMT
Release Date Price: €9.13 (-43.71%)
Operator

Good morning, and welcome to the HTG Molecular KOL event. (Operator Instructions). I'd now like to turn the call over to your host, John Lubniewski, President and Chief Executive Officer of HTG Molecular. Please go ahead, John.

John L. Lubniewski;Robert Spitale
HTG Molecular Diagnostics, Inc. - President, CEO & Director;

Thanks, Tara, and welcome, everybody, and thank you very much for dialing in to listen to what we're working on here at HTG regarding transcriptomic inform drug design. This morning it's my great privilege that we've got Dr. Robert Spitale, who's the Associate Dean of Research at the University of California at Irvine, School of Pharmacy and pharmaceutical sciences. Robert has been instrumental in helping us shape our thinking and our approach to our drug design. As a fellow upstate in New Yorker, it's really a great privilege to have him here. Although he'd probably refer to himself as a western New Yorker as opposed to an upstate. Either way, it's my great privilege to introduce Dr. Robert Spitale. Robert?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot